Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

49 50 Next >

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent ↗

October 25, 2024

Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared.

Via Benzinga

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today ↗

October 24, 2024

Via Benzinga

A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals ↗

October 23, 2024

Via Benzinga

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗

October 23, 2024

Via Benzinga

Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

October 23, 2024

Via Benzinga

Market Whales and Their Recent Bets on REGN Options ↗

October 23, 2024

Via Benzinga

What the Options Market Tells Us About Regeneron Pharmaceuticals ↗

October 10, 2024

Via Benzinga

Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry ↗

October 09, 2024

Via Benzinga

A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals ↗

October 04, 2024

Via Benzinga

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗

October 14, 2024

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Via Talk Markets

Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

October 10, 2024

Via Benzinga

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs ↗

October 07, 2024

Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects...

Via Benzinga

Market Whales and Their Recent Bets on REGN Options ↗

October 03, 2024

Via Benzinga

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗

October 03, 2024

Via Benzinga

Should You Buy the Dip on This Top Growth Stock? ↗

October 05, 2024

The biotech needs to overcome an issue most drugmakers face at some point.

Via The Motley Fool

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today ↗

September 30, 2024

Via Benzinga

Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio? ↗

September 29, 2024

10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio?

Via Benzinga

Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review ↗

September 27, 2024

The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.

Via Investor's Business Daily

Topics Stocks

A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics ↗

September 25, 2024

Via Benzinga

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗

September 25, 2024

Via Benzinga

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease ↗

September 27, 2024

The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...

Via Benzinga

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗

September 27, 2024

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Via Investor's Business Daily

Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades' ↗

September 26, 2024

Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.

Via Benzinga

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? ↗

September 24, 2024

Regeneron filed an appeal after a court's decision, which was issued under seal.

Via Benzinga

This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

September 24, 2024

Via Benzinga

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling ↗

September 23, 2024

The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.

Via Investor's Business Daily

Topics Stocks

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea ↗

September 23, 2024

Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.

Via Investor's Business Daily

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

Headline News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today